The objective of this study was to determine the incidence and risk factors associated with new-onset and worsening portal hypertensive gastropathy (PHG) in patients with chronic hepatitis C (CHC).
INTRODUCTION
Portal hypertensive gastropathy (PHG) is characterized by the presence of a mucosal mosaic pattern with focal red and brown spots, as well as vascular ectasias that may be locally or diff usely distributed in the stomach of patients with chronic liver disease or portal vein thrombosis ( 1 -3 ) . Th e severity of PHG can vary from mild to severe, and patients with PHG are at an increased risk of acute and chronic gastrointestinal bleeding ( 4 -6 ) . Th e pathogenesis of PHG is not well understood, but is believed to be related to high portal pressure and impaired gastric mucosal defenses ( 7, 8 ) . However, the incidence and risk factors for new-onset or worsening PHG in prospectively monitored patients with chronic liver disease have not been well described.
Th e Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial was a large, prospective multicenter study designed to determine whether prolonged low-dose peginterferon therapy would reduce the rate of histological and clinical disease progression among previous non-responder patients with compensated Development and Progression of Portal Hypertensive Gastropathy in Patients With Chronic Hepatitis C chronic hepatitis C (CHC) ( 9 ) . Th e HALT-C trial and other similar studies failed to demonstrate a benefi t of prolonged interferon therapy compared with no treatment in reducing the rate of disease progression ( 9 -12 ) . As it was hypothesized that interferon-treated patients may experience a reduction in portal pressure, all HALT-C trial patients underwent a baseline endoscopy before randomization and at the end of follow-up to determine the incidence of newonset and worsening gastroesophageal varices and PHG ( 13, 14 ) . In a previous analysis, 34 % of HALT-C trial patients had mild PHG at baseline and these patients had clinical and laboratory evidence of more severe liver disease compared with those without PHG ( 15 ) . In this paper, the incidence and risk factors associated with newonset PHG and worsening of baseline PHG in 831 HALT-C trial patients who underwent endoscopic surveillance are reported. Th e relationship between changes in the PHG score and clinical and histological outcomes, as well as the evolution of gastroesophageal varices are also reported.
METHODS
Previous non-responders to standard interferon with advanced fi brosis on biopsy (i.e., Ishak fi brosis score ≥ 3) with no history of hepatic decompensation or hepatocellular carcinoma (HCC) were re-treated with full-dose peginterferon and ribavirin during the " lead-in " phase of the HALT-C trial ( 9 ) . All participants had a baseline Child -Turcotte -Pugh score of either 5 or 6. Patients with persistently detectable hepatitis C virus RNA at week 20 were randomized to maintenance peginterferon α 2a 90 μ g per week (Pegasys; Roche Laboratories, Nutley, NJ) or no treatment for the next 3.5 years. Week 20 virological responders in the leadin phase continued combination therapy for 48 weeks. However, patients with detectable hepatitis C virus RNA during treatment (breakthrough) or aft er stopping treatment (relapse) were also eligible for randomization. In addition, " express " patients who had received at least 24 weeks of full-dose peginterferon and ribavirin outside the HALT-C trial with persistent viremia were eligible for enrollment in the randomized phase. Th is study was approved by the Institutional Review Board at all 10 HALT-C trial sites, and all subjects provided written informed consent for the trial and before each endoscopy.
Endoscopic evaluation and end points
A written protocol that included standardized criteria for identifying and grading the presence of esophageal varices, gastric varices, and PHG was implemented at all centers before study initiation. All subjects underwent a pretreatment baseline endoscopy before randomization, and subjects with established gastroesophageal varices at baseline underwent a repeat endoscopy at 18 months aft er randomization, which is deemed study year 2. In addition, all randomized patients who had not died or those who reached a clinical end point underwent a follow-up endoscopy at year 3.5 aft er randomization, which is deemed study year 4. Th e presence and severity of PHG were scored by the local study endoscopist according to the NIEC (New Italian Endoscopy Conference) criteria ( 2 ). In particular, the mucosal mosaic pattern was considered mild and scored 1 if there were pink, non-hemorrhagic polygonal, scale-like areas and was considered severe with a score of 2 if present throughout the mucosa with red hemorrhagic foci. Focal fl at or slightly bulging red marks were considered mild and scored 1 if found in isolated areas and were considered severe with a score of 2 if present throughout the mucosa. Gastric antral vascular ectasia (GAVE) was diagnosed by the presence of fl at or slightly raised, red stripe-like lesions radiating from the pylorus to the antrum and body of the stomach and given a score of 2. Th e presence of black-brown spots representative of old submucosal hemorrhage was not recorded. A PHG score of 0 was considered none, 1 -3 was considered mild PHG, and a score of ≥ 4 was considered severe PHG ( 4 ) . Th e presence and size of esophageal varices were graded as small (F1), medium (F2), and large (F3).
De novo PHG was defi ned as any patient without baseline PHG who had a PHG score ≥ 1 at a follow-up endoscopy or who developed upper gastrointestinal bleeding. PHG progression was defi ned as an increase in PHG score by ≥ 1 point at a follow-up endoscopy or development of upper gastrointestinal bleeding. PHG regression or improvement was defi ned as a reduction in the PHG score by ≥ 1 point. De novo varices were defi ned as newly identifi ed esophageal or gastric varices or development of variceal hemorrhage during follow-up in patients without varices at baseline ( 16 ) . Variceal progression was defi ned as an increase in esophageal varix size of at least 1 grade at year 2 or year 4 endoscopy, variceal bleeding at any time in the randomized phase, or development of new gastric varices. Th e clinical management of gastroesophageal varices and PHG was at the discretion of the local investigator.
Laboratory and clinical assessment
Routine baseline laboratory values (such as serum aminotransferases, albumin, bilirubin, platelet count) were obtained at the local laboratories. Homeostatic model assessment (HOMA) of insulin resistance was calculated as HOMA = ((insulin × glucose) / 22.5) × 0.5551 in which insulin is expressed in mU / ml and glucose in mg / dl. Serum hepatitis C virus RNA testing was performed at baseline and during the randomized phase using the quantitative COBAS Amplicor Hepatitis C Virus Monitor Test (Roche Molecular Diagnostics, Branchburg, NJ), with a lower limit of detection of 600 IU / ml at a central laboratory. Serum iron, total iron-binding capacity, total bile acids, and hyaluronic acid levels were determined at a reference laboratory (Wako Diagnostics, Richmond, VA). Liver biopsies were evaluated by a panel of expert liver pathologists and scored for the degree of hepatic fi brosis and infl ammation defi ned by the Ishak scoring system, and the degree of hepatic steatosis was estimated as grade 0 -4. Splenomegaly was defi ned by a spleen length > 13 cm on sonography.
All patients were seen every 3 months during the randomized phase for laboratory and clinical assessment. In addition, annual liver ultrasounds were obtained to screen for HCC and serum α -fetoprotein levels were obtained every 6 months. Clinical end points for the study included an increase in Child -Turcotte -Pugh score to ≥ 7 on two consecutive occasions 3 months apart, upper gastrointestinal bleeding, ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, HCC, or death. Th e end point of upper gastrointestinal bleeding was defi ned by the need for in-patient hospitalization for treatment, but whether the bleeding was due to PHG vs. varices was not recorded. Histological progression was defi ned as an increase in the Ishak fi brosis score of ≥ 2 points at year 2 or year 4 liver biopsies in non-cirrhotic patients. Th e current analysis of clinical outcomes includes patients who were followed up at the HALT-C trial sites for a median of 6 years aft er randomization.
Statistical methods
Statistical analyses were performed at the data coordinating center (New England Research Institute, Watertown, MA) using SAS soft ware, version 9.2 (SAS Institute, Cary, NC). Log transformation of non-normally distributed variables was undertaken when indicated. Bivariate logistic regression methods were used to explore factors associated with new PHG development and PHG progression. For multivariate models, individual factors that were associated with the outcome on bivariate analysis with P < 0.20 were initially included. Only variables that were signifi cant with P < 0.05 were then retained in the fi nal multivariate model. Area under the receiver operator curve (AUROC) was calculated to quantify the predictive ability of the model, ranging from 0.5 (by chance) to 1 (perfect discrimination).
RESULTS

Patient population
A baseline endoscopy was available in 1,011 (96.3 % ) of the 1,050 patients randomized in the HALT-C trial. Features of PHG were absent in 637 patients (63 % ), whereas 374 (37 % ) had PHG ( Figure 1 ). A follow-up endoscopy was available in 831 subjects, including 514 subjects without baseline PHG and 317 subjects with baseline PHG. Th e reasons for failure to undergo repeat endoscopy included development of a clinical outcome (70) including 38 deaths, withdrawal from the study (70), or patient refusal (40). Th e 180 subjects who did not undergo repeat upper endoscopy had evidence of more severe liver disease at the time of entry, including higher serum aspartate transaminase / alanine transaminase (AST / ALT) ratio and total bile acids and lower serum albumin levels, as well as a greater likelihood of developing a clinical outcome during follow-up than did those who were included (data not shown).
Development of new-onset PHG
During follow-up, 256 of the 514 subjects (50 % ) developed newonset PHG and the estimated annual rate of new-onset PHG was 12.9 % per year ( Table 1 ) . Th e PHG score at follow-up was 1 in 167 subjects, 2 in 36 subjects, and ≥ 3 in 45 subjects, and 8 had experienced gastrointestinal bleeding. Th e mucosal mosaic pattern was identifi ed in 91 % , red marks in 33 % , and GAVE features in 9 % . At baseline, those with new-onset PHG had evidence of more severe liver disease and laboratory markers of more severe portal hypertension ( Table 1 ). In addition, patients with diabetes and subjects with higher body mass index were more likely to develop new-onset PHG. However, lifetime alcohol consumption, smoking status, and subject race were not associated with new-onset PHG. Th e use of peginterferon therapy during the randomized phase was similar in those with and without new-onset PHG (52 vs. 49 % , P = 0.596).
On multivariate analysis, a higher baseline serum alkaline phosphatase level and being diabetic were signifi cantly associated with new-onset PHG. Th e AUROC for this model was 0.62 (95 % confi dence interval (95 % CI): 0.57, 0.66). Th ere was no signifi cant change in the model when baseline liver histology or baseline gastroesophageal varices were added or by removing patients who developed GAVE features alone.
Progression of baseline PHG
As expected, the 317 patients with baseline PHG had more severe liver disease compared with the 514 patients without baseline 
LIVER
Portal Gastropathy in Hepatitis C ( Figure 3 ).
Regression of PHG
During follow-up, 100 patients had an unchanged PHG score and 135 patients had an improved PHG score. Of the 135 with an improved PHG score, 99 improved by 1 point, 23 improved by 2 points, and 13 improved by ≥ 3 points. On univariate analysis, subjects with an improved PHG score were more likely to have laboratory markers indicative of a less severe liver disease (i.e., lower serum AST / ALT ratio, higher platelet counts) and were also less likely to have cirrhosis, advanced hepatic steatosis, and concomitant varices (data not shown). On multivariate analysis, subjects with an improved PHG score were less likely to have advanced hepatic steatosis (36 vs. Figure  4 , the likelihood of developing new varices was higher in patients who also had worsening PHG than in subjects without worsening PHG, but this trend was not signifi cant (34 vs. 27 % , OR = 1.41 (95 % CI: 0.66, 3.03), P = 0.38) . Finally, the likelihood of developing worsening varices was greater in subjects with worsening PHG than in those without (76 vs. 29 % , OR = 7.75 (95 % CI: 3.26, 18.45), P < 0.0001).
DISCUSSION
Portal hypertensive gastropathy is the most common gastric mucosal injury pattern reported in patients with chronic liver disease ( 17 ) . Th e frequency and severity of PHG are greater in patients with decompensated cirrhosis than with compensated cirrhosis ( 3,5,17 ) . However, PHG is a dynamic lesion that can PHG, including more frequent cirrhosis (55 vs. 33 % , P < 0.0001), esophageal varices (42 vs. 18 % , P < 0.0001), and higher total bilirubin levels (0.87 vs. 0.75 mg / dl, P < 0.001). During follow-up, the 317 patients with baseline PHG also had a higher incidence of clinical outcomes (35 vs. 16 % , P < 0.0001). Th e severity of baseline PHG was mild in 92 % and severe in 8 % with total PHG scores of 1 in 186 subjects, 2 in 76 subjects, and ≥ 3 in 55 subjects. Th e mucosal mosaic pattern was identifi ed in 92 % , red marks in 42 % , and GAVE features in only 11 % .
During follow-up, 82 of the 317 (26 % ) patients with baseline PHG had a worsening of their PHG score by at least 1 point with an estimated annual rate of 6.7 % per year. Among these 82 patients, 27 had an increase in their PHG score of only 1 point, 16 had an increase of 2 points, and 21 had an increase of ≥ 3 points while 18 others had gastrointestinal hemorrhage. Th e proportion of patients with worsening or new mosaic pattern was 93 % , worsening or new red marks was 79 % , and new-onset GAVE was 36 % . Subjects with PHG progression were more likely to be Caucasian and have underlying cirrhosis and baseline laboratory parameters suggestive of more severe liver disease with lower platelet counts and higher serum AST / ALT ratio, hyaluronic acid, total bile acids, and HOMA and total bilirubin levels ( Table 2 ). However, lifetime alcohol consumption and receipt of peginterferon during the randomized phase were not diff erent nor was the frequency of β -blocker or non-steroidal anti-infl ammatory drug use at baseline.
On multivariate analysis, Caucasian race, lower platelets and albumin, and higher baseline serum AST / ALT ratio and HOMA levels were signifi cantly associated with PHG progression. Th e AUROC of this model was 0.78 (95 % CI: 0.71, 0.84). When baseline liver histology and gastroesophageal varices were added to the model, the AUROC remained unchanged.
Evolution of PHG and clinical outcomes
Among the 514 patients without PHG at baseline, 82 subjects (16 % ) developed one or more clinical outcomes during a median follow-up of 6 years. Th e specifi c clinical outcomes included 61 with worsening Child -Turcotte -Pugh, 22 HCCs, 39 deaths, and 30 liver transplants. Th e likelihood of developing a clinical outcome was signifi cantly higher in the 256 subjects with new-onset PHG than in the 258 CHC patients without new-onset PHG (25 vs. 7 % , odds ratio (OR) = 4.11 (95 % CI: 2.38, 7.10), P < 0.0001) ( Figure 2 ). We also investigated the relationship between new-onset PHG and histological progression in 337 non-cirrhotic HALT-C trial patients. As shown in Figure 3 , histological progression was signifi cantly more common in subjects with new-onset PHG compared with those who did not develop PHG during follow-up (33 vs. 23 % , OR = 1.71 (95 % CI: 1.06, 2.76), P = 0.030).
Among the 317 subjects with PHG at baseline, 112 (35 % ) developed one or more clinical outcomes during follow-up, which included 82 with a worsening Child -Turcotte -Pugh score, 28 HCCs, 44 deaths, and 35 liver transplants. As per Figure 2 , the 82 subjects with worsening PHG were signifi cantly more likely to also experience a clinical outcome compared with the 235 subjects without worsening PHG (55 vs. 29 % , OR = 3.05 (95 % CI: 1.81, 5.12), P < 0.0001). In addition, the 21 non-cirrhotic patients with
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Portal Gastropathy in Hepatitis C new-onset PHG experienced gastrointestinal bleeding. However, a clinical outcome was signifi cantly more likely to develop in subjects with new-onset PHG compared with subjects without newonset PHG (25 vs. 7 % ). In addition, non-cirrhotic subjects with new-onset PHG were signifi cantly more likely to develop worsening hepatic fi brosis compared with those without PHG (33 vs.
% )
. Th ese data demonstrate that new-onset PHG directly correlates with global worsening of liver disease status in a large cohort of well-characterized CHC patients. On multivariate analysis, independent risk factors for the development of new-onset PHG included a higher serum alkaline phosphatase level and being diabetic. Serum alkaline phosphatase levels have been previously associated with more severe liver disease in CHC patients ( 21, 22 ) . Th e positive association with diabetes suggests that subjects with the metabolic syndrome may be at increased risk of developing new-onset PHG. In support of this, the prevalence of diabetes and hypertension was higher in subjects with new-onset PHG, but the proportion with signifi cant hepatic steatosis and baseline HOMA levels were not higher compared with those without new-onset PHG ( Table 1 ). On the basis of previous studies, we had anticipated that peginterferon-treated patients in HALT-C would have a lower likelihood of developing new-onset PHG or varices ( 13, 14 ) . However, peginterferon therapy was neither associated with a reduced risk of new-onset PHG nor with varices. Th e greater frequency of β -blocker use in those with new-onset PHG may be due to the greater likelihood of those patients also having baseline gastroesophageal varices (29 vs. 8 % , P < 0.0001).
During follow-up, 26 % of patients with baseline PHG had a worsening of their PHG score. Th e endoscopic feature that most commonly worsened was the mucosal mosaic pattern and most subjects had an increase in their score of only 1 point. Nonetheless, 22 % of these patients with worsening PHG had a documented episode of upper gastrointestinal bleeding. Th ese observations are consistent with previous reports of a greater short-term risk of upper gastrointestinal bleeding in patients with severe vs. mild PHG ( 23, 24 ) . In addition, subjects with worsening PHG were also at a much higher risk of experiencing a clinical complication from their liver disease than were those with stable or improved PHG. Similarly, non-cirrhotic patients with worsening PHG were significantly more likely to have fi brosis progression ( Figures 2 and 3 ) . Th ese data confi rm the strong positive correlation between worsening endoscopic stigmata of portal hypertension and the clinical and histological progression of CHC.
On multivariate analysis, independent risk factors for PHG worsening included Caucasian race, lower serum albumin, and higher serum AST / ALT ratio and HOMA levels. Th ese fi ndings are consistent with our previous analyses demonstrating that African Americans with CHC are less likely to have baseline PHG or varices and also less likely to develop new-onset gastroesophageal varices ( 15, 16, 20 ) . Th ese data are also consistent with other studies that indicate that African Americans with CHC tend to have less severe hepatic necroinfl ammation and steatosis compared with Caucasians at presentation and during followup ( 25 -27 ) . If confi rmed in other studies, it is possible that develop aft er variceal band ligation or other events that increase portal resistance and also spontaneously regress over time ( 18, 19 ) . In the current study, we set out to determine the incidence and risk factors for new-onset and worsening PHG in patients who underwent a repeat endoscopy aft er a mean followup of 4 years.
New-onset PHG developed in 50 % of HALT-C trial patients, and the rate of new-onset PHG was over two times the rate of newonset varices in this same cohort (12.9 vs. 5.2 % ) ( 20 ) . Th e majority of patients with new-onset PHG had low PHG scores during follow-up and the mucosal mosaic pattern was the most commonly reported feature. During follow-up, only 3 % of patients with 
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Portal Gastropathy in Hepatitis C endoscopic surveillance strategies in CHC patients with advanced fi brosis may not need to be as frequent in African Americans vs. other groups. Th e positive associations of the various laboratory parameters with the risk of worsening PHG presumably refl ect patients who had more advanced disease at baseline. Th e absence of any benefi cial eff ect of peginterferon therapy on the worsening of PHG or baseline varices confi rms the lack of any portal hypotensive eff ect with the doses of peginterferon used in the HALT-C trial ( 20 ) . Th e strengths of our study include the large number of wellcharacterized patients who underwent serial liver biopsy, frequent study visits, and protocol endoscopies in this multicenter prospective study. In addition, baseline laboratory and clinical parameters were collected in a uniform manner. Furthermore, all of these patients had the same etiology of liver disease with no previous history of gastrointestinal bleeding or banding of varices allowing us to eff ectively conduct a prospective natural history study of liver disease progression and evolution of endoscopic fi ndings. Finally, the overall compliance with the recommended endoscopy surveillance schedule was high with > 80 % of eligible patients completing the follow-up exam. Th e limitations of our study include the lack of centralized review of the endoscopic fi ndings, which was not possible because of limited resources. However, a standardized manual of procedures and training was provided to all sites before and during the study. In addition, it was not possible to perform baseline or serial portal pressure measurements because of the cost, risk, and inconvenience. However, recent studies have failed to demonstrate a consistent relationship between portal pressure measurements and the frequency and severity of PHG ( 17 ) . Finally, the criteria to defi ne new-onset or worsening PHG have not been well standardized. A previous study had validated the PHG scoring system used in our study with an excellent interobserver agreement and correlation with the risk of bleeding during follow-up ( 24 ) . Th e strong association of PHG with clinical and histological outcomes ( Figures 2 and 3 ) further confi rms that a 1-point increase in the PHG score is clinically meaningful. In addition, the strong positive association between new-onset and worsening PHG with new-onset varices ( Figure 4 ) and variceal progression ( Figure 5 ) further validates the clinically utility of a 1-point increase in the PHG score in CHC patients. Finally, the lower likelihood of clinical and histological disease progression noted in subjects with an improved PHG score over time further supports the utility of monitoring the severity of PHG in individual patients.
In summary, 50 % of CHC patients enrolled in the HALT-C trial developed new-onset PHG during 4 years of follow-up. Th e majority of patients had mild PHG and only 3 % bled during follow-up. In contrast, 26 % of patients with baseline PHG had worsening of PHG over time and the risk of bleeding was substantially higher in these patients. In both subgroups of patients, PHG onset or worsening was strongly associated with clinical and histological progression of liver disease. Furthermore, new-onset or worsening PHG was strongly associated with the development or worsening of gastroesophageal varices. A model to predict patients at high risk of new-onset PHG was developed, but the low AUROC may limit its clinical utility. In contrast, the model to identify patients at high risk for worsening PHG may potentially be useful to clinicians. Finally, our data support an emerging body of evidence that the initial and subsequent risk of endoscopic stigmata of portal hypertension may vary substantially by subject ethnicity in CHC patients ( 25 -27 ) .
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